TrialPharmacoEconomics2019

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.

Eytan Stein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.